Cardiff Oncology, Inc. is focused on developing innovative cancer therapies through the inhibition of Polo-like kinase 1 (PLK1). Their lead candidate, onvansertib, is being evaluated in various clinical trials, particularly in combination with standard of care (SoC) treatments for cancers such as metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company aims to address significant treatment gaps by targeting specific tumor vulnerabilities, especially in patients with RAS mutations, to enhance clinical outcomes and overcome resistance to existing therapies.

The clinical programs currently underway include a Phase 2 trial (CRDF-004) for first-line RAS-mutated metastatic colorectal cancer, where onvansertib is tested alongside established treatment regimens. Additionally, there are ongoing trials assessing the efficacy of onvansertib in second-line settings and in combination with other chemotherapeutic agents. Through these initiatives, Cardiff Oncology seeks to provide new therapeutic options that could lead to improved response rates and progression-free survival for patients facing challenging cancer diagnoses.

United States

Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. 

Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). 

These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.


Cancer

Cardiff Oncology, Inc.

Castration-resistant prostate cancer

Prostate cancer

<p class="font_7">An oral and highly-selective inhibitor of Polo-like Kinase 1 (PLK1), in combination with standard-of-care therapeutics, to overcome resistance to current therapies, improve efficacy and increase overall survival in solid tumor and hematologic cancers.</p>

Onvansertib + Zytiga (abiraterone)

Pancreatic cancer

Solid tumor/s

Onvansertib + nanoliposomal irinotecan (Onyvide®) (PLK1)

Small cell lung cancer

Onvansertib (monotherapy)

Metastatic colorectal cancer

Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab)

Triple-negative breast cancer

Onvansertib + Paclitaxel

Colorectal cancer

<p class="font_7">An oral and highly-selective inhibitor of Polo-like Kinase 1 (PLK1), in combination with standard-of-care therapeutics (e.g. FOLFIRI/Avastin), to overcome resistance to current therapies, improve efficacy and increase overall survival in solid tumor and hematologic cancers.</p>

Cardiff Oncology, Inc.

Company Details